| Literature DB >> 23091538 |
Sang-Hoon Cho1, Jongsu Jeon, Seung Il Kim.
Abstract
The recent advent of "-omics" technologies have heralded a new era of personalized medicine. Personalized medicine is referred to as the ability to segment heterogeneous subsets of patients whose response to a therapeutic intervention within each subset is homogeneous. This new paradigm in healthcare is beginning to affect both research and clinical practice. The key to success in personalized medicine is to uncover molecular biomarkers that drive individual variability in clinical outcomes or drug responses. In this review, we begin with an overview of personalized medicine in breast cancer and illustrate the most encountered statistical approaches in the recent literature tailored for uncovering gene signatures.Entities:
Keywords: Biomarker discovery; Breast neoplasms; Individualized medicine; Predictive biomarker; Prognostic biomarker
Year: 2012 PMID: 23091538 PMCID: PMC3468779 DOI: 10.4048/jbc.2012.15.3.265
Source DB: PubMed Journal: J Breast Cancer ISSN: 1738-6756 Impact factor: 3.588